Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis

• Published in: Amyotrophic lateral sclerosis and frontotemporal degeneration 2024, Vol.25 (1-2), p.150-161
• Main Authors: Kläppe, Ulf, Sennfält, Stefan, Lovik, Anikó, Finn, Anja, Bofaisal, Ulrika, Zetterberg, Henrik, Blennow, Kaj, Piehl, Fredrik, Kmezic, Ivan, Press, Rayomand, Samuelsson, Kristin, Månberg, Anna, Fang, Fang, Ingre, Caroline
• Format: Article
• Language: English
• Subjects: Amyotrophic Lateral Sclerosis; Biomarkers; Case-Control Studies; Humans; Medicin och hälsovetenskap; Neurofilament Proteins - cerebrospinal fluid; Neuroinflammatory Diseases; Neurosciences; Neurovetenskaper; Prognosis
• ISSN: 2167-8421; 2167-9223; 2167-9223
• DOI: 10.1080/21678421.2023.2263874

To describe the diagnostic and prognostic performance, and longitudinal trajectories, of potential biomarkers of neuroaxonal degeneration and neuroinflammation in amyotrophic lateral sclerosis (ALS). This case-control study included 192 incident ALS patients, 42 ALS mimics, 114 neurological controls, and 117 healthy controls from Stockholm, Sweden. Forty-four ALS patients provided repeated measurements. We assessed biomarkers of (1)neuroaxonal degeneration: neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in cerebrospinal fluid (CSF) and NfL in serum, and (2)neuroinflammation: chitotriosidase-1 (CHIT1) and monocyte chemoattractant protein 1 (MCP-1) in CSF. To evaluate diagnostic performance, we calculated the area under the curve (AUC). To estimate prognostic performance, we applied quantile regression and Cox regression. We used linear regression models with robust standard errors to assess temporal changes over time. Neurofilaments performed better at differentiating ALS patients from mimics (AUC: pNfH 0.92, CSF NfL 0.86, serum NfL 0.91) than neuroinflammatory biomarkers (AUC: CHIT1 0.71, MCP-1 0.56). Combining biomarkers did not improve diagnostic performance. Similarly, neurofilaments performed better than neuroinflammatory biomarkers at predicting functional decline and survival. The stratified analysis revealed differences according to the site of onset: in bulbar patients, neurofilaments and CHIT1 performed worse at predicting survival and correlations were lower between biomarkers. Finally, in bulbar patients, neurofilaments and CHIT1 increased longitudinally but were stable in spinal patients. Biomarkers of neuroaxonal degeneration displayed better diagnostic and prognostic value compared with neuroinflammatory biomarkers. However, in contrast to spinal patients, in bulbar patients neurofilaments and CHIT1 performed worse at predicting survival and seemed to increase over time.